Navigation Links
Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
Date:3/18/2009

for both chemo-naive and post-chemo patients. MDV3100 has been generally well tolerated at doses of up to and including 240 mg/day. The most frequently reported adverse event was fatigue. Patients are continuing on study until they experience an intolerable adverse event or until their disease progresses. Additional data from this trial are expected to be presented at upcoming medical conferences.

About Prostate Cancer and MDV3100

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. In 2008, an estimated 186,320 new cases were expected to be diagnosed and approximately 28,660 men were expected to die from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Overexpression of the androgen receptor is believed to contribute to the progression of castration-resistant prostate cancer. MDV3100 is a novel small-molecule androgen receptor antagonist that inhibits androgen receptor function by blocking nuclear translocation of the androgen receptor and DNA binding.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
2. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
5. Medivation Announces Participation in Upcoming Conferences
6. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
7. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
8. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
9. Urban Health Plan Receives $1.3M from Economic Stimulus Package to Increase Health Care Access in Corona, Queens
10. CUREXO Technology Corporation Receives Quality Certificate
11. Silk Information Systemss Silk V 4.2 Receives 08 CCHIT Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... (PRWEB) July 13, 2014 Manchester United ... with the 2014 Guinness International Champions Cup. The 2014 ... soil each year because of the talent of it brings ... and AS Roma will compete in the 2014 event spread ... July 24 with a game between Olympiacos and Milan and ...
(Date:7/13/2014)... An editorial published today in The Lancet ... into consideration the long term neurological problems that ... the most common form of sports-related traumatic brain ... concussions may include dementia, amyotrophic lateral sclerosis, and ... what is perhaps more concerning, is that even ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Intraocular Lens ... and Forecast 2013 - 2019 , Intraocular lens (IOL) ... from myopia or cataracts. The lenses are inserted inside ... cataract surgery intraocular lens replaces the focusing power of ... original crystalline lens to deliver the light focusing function ...
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from China, has announced ... company’s chief executive officer has announced a new promotion for ... at discounted prices, from 15 to 26 percent off. , ... huge demand in the current market. We are excited to ... lot of high quality products for sale. Many of our ...
(Date:7/13/2014)... July 13, 2014 The report ... Molybdenum, Iron), Form (Chelated & Non Chelated), Application ... - Global Trends and Forecast to 2018” defines ... an analysis and forecasting of the global value ... the driving and restraining factors for the global ...
Breaking Medicine News(10 mins):Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4
... Specialties, Mfg. is pleased to announce the introduction of push-to-connect ... Mfg and designed with John Guest push-to-connect style fittings integrated ... offers versatility and customization for a variety of applications. ... ...
... Oct. 7 ProGenTech Limited, a life,sciences & ... CA,has signed a licensing agreement with Human Genetic ... gain access to key,hospital-acquired infection targets, payment terms ... the agreement, Human Genetic Signatures will develop,assays for ...
... for food-allergic kids and their parents. All kids want to join in ... they can…as long as they steer clear of the foods that pose ... ... EON) October 6, 2008 -- Enjoy Life Foods, the country,s leader ...
... VOLC ), a leader in the development, ... treatment of coronary and peripheral artery,disease, today announced ... Rancho Cordova to San Diego. The new corporate,headquarters ... San Diego and now,houses corporate executives, marketing, finance, ...
... The United States has,intervened in a lawsuit ... claims to Medicare arising from illegal kickbacks ... (DME) suppliers, the,Justice Department announced today. The ... (MediNet), GGNSC Holdings LLC,Golden Gate Ancillary LLC, ...
... presented at the American College of Gastroenterology Annual ... TAK-390MR resulted in higher healing rates than lansoprazole ... esophagitis (EE). TAK-390MR combines dexlansoprazole with a Dual ... separate releases of drug for extended duration of ...
Cached Medicine News:Health News:ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal 2Health News:ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal 3Health News: Enjoy Life Foods Teams with AllergyMoms.com to Ensure Halloween Isn't 'Tricky' for Food-Allergic Kids and Families : Provides tips for being allergy-aware this Halloween 2Health News: Enjoy Life Foods Teams with AllergyMoms.com to Ensure Halloween Isn't 'Tricky' for Food-Allergic Kids and Families : Provides tips for being allergy-aware this Halloween 3Health News: Enjoy Life Foods Teams with AllergyMoms.com to Ensure Halloween Isn't 'Tricky' for Food-Allergic Kids and Families : Provides tips for being allergy-aware this Halloween 4Health News:Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego 2Health News:Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego 3Health News:Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego 4Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Takeda's investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole 2
(Date:7/13/2014)... -- Eli Lilly and Company (NYSE: LLY ... in genetically engineered mice examining combination therapy with ... and beta-secretase inhibitor BACE (LY2811376). Data results found ... clumps of amyloid-beta protein in the brain – ... Alzheimer,s disease (AD) – than use of one ...
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, Inc. ... today announced that the Food and Drug Administration ("FDA"), ... comments on RCP,s Investigational New Drug ("IND") application before ... in the US. Dr. Chris Chapman ... and comments on our IND. When we receive the ...
(Date:7/11/2014)... 2014  Kindred Hospital Houston Northwest, with Wound ... of its new outpatient wound healing center.  The ... with chronic, hard to heal wounds. Chronic wounds ... amputation, lower leg wounds related to blood flow ... traumatic injury wounds which are complex and demonstrate ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2
... The board of directors of Hospira, Inc. (NYSE: ... today announced that Christopher B. Begley, chairman and chief executive ... CEO position after more than six years of dedicated service. ... He will then remain an employee of the company as ...
... Amsterdam Next April 2011 -- AMSTERDAM, August 20, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Medicine Technology:Hospira Announces CEO Succession Plan 2Hospira Announces CEO Succession Plan 3Hospira Announces CEO Succession Plan 4Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 2Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 3Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 4Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 5Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 6
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: